{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T04:25:29Z","timestamp":1774412729472,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die okul\u00e4re Toxoplasmose (OT) ist die h\u00e4ufigste infekti\u00f6se Ursache einer posterioren Uveitis. Diese Erhebung soll das derzeitige diagnostische und therapeutische Vorgehen bei OT in Deutschland evaluieren.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Ein detaillierter Fragebogen mit spezifischen Patientenbeispielen wurde im Juli 2021 an die Mitglieder der Sektion Uveitis der Deutschen Ophthalmologischen Gesellschaft (DOG) und der Retinologischen Gesellschaft (RG) versandt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Der Fragebogen wurde von 53 (29\u00a0RG und 24\u00a0DOG) Ophthalmologen beantwortet. Sechzehn (30\u202f%) Befragte arbeiten in einer Praxis, 18 (34\u202f%) in einer Klinik und 19 (36\u202f%) in einer Universit\u00e4tsklinik. Neun (17\u202f%) Augen\u00e4rzte (A\u00c4) betreuen weniger als 50, 28 (53\u202f%) 50 bis 200 und 16 (30\u202f%) mehr als 200\u00a0Uveitispatienten pro Jahr. Der klinische Befund gilt weiterhin als Goldstandard (87\u202f%) f\u00fcr die Diagnose der OT und wird bei Erstmanifestation in 60\u202f% durch spezifische serologische Antik\u00f6rperuntersuchungen unterst\u00fctzt. Eine Diagnose allein anhand des klinischen Befundes stellen 10\u00a0von 53 (19\u202f%) A\u00c4, 25 (47\u202f%) Befragte st\u00fctzen sich auf einen Ig(Immunglobulin)M-Test, 6 (11\u202f%) erwarteten einen IgG-Titer-Anstieg und einer (2\u202f%) den Nachweis spezifischer IgA-Antik\u00f6rper. Die Mehrheit (<jats:italic>n<\/jats:italic>\u202f=\u200928 [53\u202f%]) der A\u00c4 w\u00fcrde die Diagnose im Zweifelsfall durch eine Vorderkammerpunktion sichern; dabei pr\u00e4ferieren 20 (38\u202f%) die Polymerasekettenreaktion (PCR), 3 (6\u202f%) die Bestimmung des Goldmann-Witmer-Koeffizienten und 5 (9\u202f%) eine Kombination beider Verfahren. Zur Therapie wurde am h\u00e4ufigsten Clindamycin eingesetzt (<jats:italic>n<\/jats:italic>\u202f=\u200921 [40\u202f%]), gefolgt von Pyrimethamin\/Sulfadiazin (<jats:italic>n<\/jats:italic>\u202f=\u200917 [32\u202f%]) und Trimethoprim\u202f+\u2009Sulfamethoxazol (TMP\/SMX) (<jats:italic>n<\/jats:italic>\u202f=\u200910 [19\u202f%]); Letzteres wird auch (<jats:italic>n<\/jats:italic>\u202f=\u200940 [75\u202f%]) zur Sekund\u00e4rprophylaxe eingesetzt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerungen<\/jats:title>\n                <jats:p>Die Ergebnisse lassen neben dem klinischen Befund als \u201eGoldstandard\u201c zur Diagnosestellung kein einheitliches Vorgehen zu Diagnose und Therapie der OT erkennen. Die hohe Nachfrage nach Serum-IgM-Antik\u00f6rpern weist auf eine weitverbreitete Unsicherheit \u00fcber die Bedeutung serologischer Befunde hin. Dies ist angesichts der weiterhin hohen Seropr\u00e4valenz in Deutschland kritisch zu werten.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-022-01691-7","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T10:03:08Z","timestamp":1658829788000},"page":"191-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnostik und Behandlung der okul\u00e4ren Toxoplasmose","Diagnostics and treatment of ocular toxoplasmosis"],"prefix":"10.1007","volume":"120","author":[{"given":"A.","family":"Taghavi-Eraghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. G.","family":"Garweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"1691_CR1","doi-asserted-by":"publisher","first-page":"CR296","DOI":"10.12659\/MSM.882735","volume":"18","author":"K Balaskas","year":"2012","unstructured":"Balaskas\u00a0K, Vaudaux\u00a0J, Boillat-Blanco\u00a0N et al (2012) Azithromycin versus sulfadiazine and pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a\u00a0pilot study. Med Sci Monit 18:CR296\u2013CR302","journal-title":"Med Sci Monit"},{"key":"1691_CR2","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00417-019-04313-2","volume":"257","author":"J Blot","year":"2019","unstructured":"Blot\u00a0J, Aptel\u00a0F, Chumpitazi\u00a0BFF et\u00a0al (2019) Monitoring of visual field over 6\u00a0months after active ocular toxoplasmosis. Graefes Arch Clin Exp Ophthalmol 257:1481\u20131488","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1691_CR3","first-page":"100661","volume":"18","author":"DA Cort\u00e9s","year":"2020","unstructured":"Cort\u00e9s\u00a0DA, Aguilar\u00a0MC, R\u00edos\u00a0HA et al (2020) Severe acute multi-systemic failure with bilateral ocular toxoplasmosis in immunocompetent patients from urban settings in Colombia: case reports. Am J Ophthalmol 18:100661\u2013100661","journal-title":"Am J Ophthalmol"},{"key":"1691_CR4","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1007\/s00436-021-07282-w","volume":"120","author":"G De Lima Bessa","year":"2021","unstructured":"De Lima Bessa\u00a0G, De Almeida\u00a0VRW, Dos\u00a0SM-DE (2021) Toxoplasma gondii in South America: a\u00a0differentiated pattern of spread, population structure and clinical manifestations. Parasitol Res 120:3065\u20133076","journal-title":"Parasitol Res"},{"key":"1691_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13643-021-01758-7","volume":"10","author":"JE Feliciano-Alfonso","year":"2021","unstructured":"Feliciano-Alfonso\u00a0JE, Mu\u00f1oz-Ortiz\u00a0J, Mar\u00edn-Noriega\u00a0MA et al (2021) Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis. Syst Rev 10:206","journal-title":"Syst Rev"},{"key":"1691_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ajo.2019.12.025","volume":"213","author":"FJP Fernandes","year":"2020","unstructured":"Fernandes\u00a0FJP, Cavalcanti\u00a0LRP, Grupenmacher\u00a0AT et al (2020) Long-term results of trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrent toxoplasma gondii retinochoroiditis. Am J Ophthalmol 213:195\u2013202","journal-title":"Am J Ophthalmol"},{"key":"1691_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3390\/jcm10051090","volume":"10","author":"JG Garweg","year":"2021","unstructured":"Garweg\u00a0JG, Pleyer\u00a0U (2021) Treatment strategy in human ocular toxoplasmosis: why antibiotics have failed. J\u00a0Clin Med 10:1090","journal-title":"J Clin Med"},{"key":"1691_CR8","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3201\/eid2708.203740","volume":"27","author":"A Krings","year":"2021","unstructured":"Krings\u00a0A, Jacob\u00a0J, Seeber\u00a0F et\u00a0al (2021) Estimates of toxoplasmosis incidence based on healthcare claims data, Germany, 2011\u20132016. Emerging Infect Dis 27:2097\u20132106","journal-title":"Emerging Infect Dis"},{"key":"1691_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.preteyeres.2013.12.005","volume":"39","author":"M Maenz","year":"2014","unstructured":"Maenz\u00a0M, Schl\u00fcter\u00a0D, Liesenfeld\u00a0O et\u00a0al (2014) Ocular toxoplasmosis past, present and new aspects of an old disease. Prog Retin Eye Res 39:77\u2013106","journal-title":"Prog Retin Eye Res"},{"key":"1691_CR10","doi-asserted-by":"publisher","first-page":"e0127683","DOI":"10.1371\/journal.pone.0127683","volume":"10","author":"Y Ouyang","year":"2015","unstructured":"Ouyang\u00a0Y, Li\u00a0F, Shao\u00a0Q et\u00a0al (2015) Subretinal fluid in eyes with active ocular toxoplasmosis observed using spectral domain optical coherence tomography. PLoS ONE 10:e127683\u2013e127683","journal-title":"PLoS ONE"},{"key":"1691_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/09273948.2018.1433303","volume":"27","author":"SW Park","year":"2019","unstructured":"Park\u00a0SW, Kim\u00a0SH, Kwon\u00a0HJ et al (2019) Diagnostic value of positive findings of toxoplasma gondii-specific immunoglobulin M serum antibody in uveitis patients to confirm ocular toxoplasmosis. Ocular Immunol Inflamm 27:583\u2013590","journal-title":"Ocular Immunol Inflamm"},{"key":"1691_CR12","first-page":"435","volume":"116","author":"U Pleyer","year":"2019","unstructured":"Pleyer\u00a0U, Gro\u00df\u00a0U, Schl\u00fcter\u00a0D et\u00a0al (2019) Toxoplasmose in Deutschland. Dtsch Arztebl Int 116:435\u2013444","journal-title":"Dtsch Arztebl Int"},{"key":"1691_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1055\/a-1141-3812","volume":"237","author":"U Pleyer","year":"2020","unstructured":"Pleyer\u00a0U, Ness\u00a0T, Garweg\u00a0J (2020) Rezidivprophylaxe bei okul\u00e4rer Toxoplasmose. Wann? Wie? F\u00fcr wen? Klin Monbl Augenheilkd 237:599\u2013604","journal-title":"Klin Monbl Augenheilkd"},{"key":"1691_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/aos.12851","volume":"94","author":"M Roh","year":"2016","unstructured":"Roh\u00a0M, Yasa\u00a0C, Cho\u00a0H et\u00a0al (2016) The role of serological titres in the diagnosis of ocular toxoplasmosis. Acta Ophthalmol 94:521\u2013522","journal-title":"Acta Ophthalmol"},{"key":"1691_CR15","first-page":"100745","volume":"19","author":"M Sigle","year":"2020","unstructured":"Sigle\u00a0M, El Atrouni\u00a0W, Ajlan\u00a0RS (2020) Seronegative ocular toxoplasma panuveitis in an immunocompetent patient. Am J Ophthalmol 19:100745","journal-title":"Am J Ophthalmol"},{"key":"1691_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ophtha.2010.04.020","volume":"118","author":"M Soheilian","year":"2011","unstructured":"Soheilian\u00a0M, Ramezani\u00a0A, Azimzadeh\u00a0A et\u00a0al (2011) Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 118:134\u2013141","journal-title":"Ophthalmology"},{"key":"1691_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ajo.2021.03.042","volume":"228","author":"The Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","unstructured":"The Standardization of Uveitis Nomenclature (SUN) Working Group (2021) Classification criteria for toxoplasmic retinitis. Am J Ophthalmol 228:134\u2013141","journal-title":"Am J Ophthalmol"},{"key":"1691_CR18","first-page":"1023","volume-title":"Diagnostik und Behandlung der okul\u00e4ren Toxoplasmose: Eine Bestandsaufnahme unter deutschsprachigen Ophthalmologen","author":"N Torun","year":"2008","unstructured":"Torun\u00a0N, Sherif\u00a0Z, Garweg\u00a0JG et\u00a0al (2008) Diagnostik und Behandlung der okul\u00e4ren Toxoplasmose: Eine Bestandsaufnahme unter deutschsprachigen Ophthalmologen Bd. 105, S\u00a01023\u20131028"},{"key":"1691_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/09273948.2011.547157","volume":"19","author":"D Wakefield","year":"2011","unstructured":"Wakefield\u00a0D, Cunningham\u00a0ET Jr., Pavesio\u00a0C et\u00a0al (2011) Controversies in ocular toxoplasmosis. Ocul Immunol Inflamm 19:2\u20139","journal-title":"Ocul Immunol Inflamm"},{"key":"1691_CR20","doi-asserted-by":"publisher","first-page":"22551","DOI":"10.1038\/srep22551","volume":"6","author":"H Wilking","year":"2016","unstructured":"Wilking\u00a0H, Thamm\u00a0M, Stark\u00a0K et al (2016) Prevalence, incidence estimations, and risk factors of toxoplasma gondii infection in Germany: a\u00a0representative, cross-sectional, serological study. Sci Rep 6:22551","journal-title":"Sci Rep"},{"key":"1691_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2022-321091","author":"K Yogeswaran","year":"2022","unstructured":"Yogeswaran\u00a0K, Furtado\u00a0JM, Bodaghi\u00a0B, Matthews\u00a0JM, Smith\u00a0JR, International Ocular Toxoplasmosis Study Group (2022) Current practice in the management of ocular toxoplasmosis.  Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2022-321091","journal-title":"Br J Ophthalmol"},{"key":"1691_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.actatropica.2018.04.026","volume":"185","author":"Y Zhang","year":"2018","unstructured":"Zhang\u00a0Y, Lin\u00a0X, Lu\u00a0F (2018) Current treatment of ocular toxoplasmosis in immunocompetent patients: a\u00a0network meta-analysis. Acta Trop 185:52\u201362","journal-title":"Acta Trop"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-022-01691-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-022-01691-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-022-01691-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T12:09:47Z","timestamp":1675426187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-022-01691-7"}},"subtitle":["Ergebnisse einer Umfrage","Results of a survey"],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1691"],"URL":"https:\/\/doi.org\/10.1007\/s00347-022-01691-7","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"23 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Taghavi-Eraghi, J.\u00a0Garweg und U.\u00a0Pleyer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}